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While interleukin (IL)-1β is a potent pro-inflammatory cytokine involved in host defense, 
high levels can cause life-threatening sterile inflammation including systemic inflammatory 
response syndrome. Hence, the control of IL-1β secretion is of outstanding biomedical 
importance. In response to a first inflammatory stimulus such as lipopolysaccharide, 
pro-IL-1β is synthesized as a cytoplasmic inactive pro-form. Extracellular ATP originating 
from injured cells is a prototypical second signal for inflammasome-dependent matura-
tion and release of IL-1β. The human anti-protease alpha-1 antitrypsin (AAT) and IL-1β 
regulate each other via mechanisms that are only partially understood. Here, we demon-
strate that physiological concentrations of AAT efficiently inhibit ATP-induced release 
of IL-1β from primary human blood mononuclear cells, monocytic U937 cells, and rat 
lung tissue, whereas ATP-independent IL-1β release is not impaired. Both, native and 
oxidized AAT are active, suggesting that the inhibition of IL-1β release is independent 
of the anti-elastase activity of AAT. Signaling of AAT in monocytic cells involves the lipid 
scavenger receptor CD36, calcium-independent phospholipase A2β, and the release 
of a small soluble mediator. This mediator leads to the activation of nicotinic acetyl-
choline receptors, which efficiently inhibit ATP-induced P2X7 receptor activation and 
inflammasome assembly. We suggest that AAT controls ATP-induced IL-1β release from 
human mononuclear blood cells by a novel triple-membrane-passing signaling pathway. 
This pathway may have clinical implications for the prevention of sterile pulmonary and 
systemic inflammation.
Keywords: cD36, chrna7, chrna9, chrna10, inflammasome, interleukin-1β, calcium-independent 
phospholipase a2β, P2X7 receptor
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inTrODUcTiOn
Interleukin (IL)-1β is a potent pro-inflammatory cytokine that 
plays a central role in host defense against infections and is mainly 
produced by monocytes, macrophages, and dendritic cells. 
Excessive systemic release of IL-1β, however, strongly contribu-
tes to the pathogenesis of life-threatening systemic inflammatory 
diseases including systemic inflammatory response syndrome 
(SIRS) (1). Release of IL-1β is strictly controlled and often depends 
on two consecutive danger signals. Lipopolysaccharide (LPS), a 
major cell wall component of Gram-negative bacteria, is a typical 
first signal that induces the biosynthesis of pro-IL-1β, an inactive 
cytoplasmic precursor of IL-1β. Numerous sterile and infec-
tious signals can trigger the assembly of diverse multi-protein 
complexes, so-called inflammasomes that activate proteases to 
cleave pro-IL-1β (2). Extracellular ATP, mainly originating from 
the cytoplasm of damaged cells, is a typical second signal. ATP 
activates the purinergic receptor P2X7 (P2X7R) and enables an 
outward current of potassium ions (2). Reduced cytoplasmic 
potassium concentrations trigger the assembly of the NLRP3 
(NACHT, LRR, and PYD domains-containing protein 3)-con-
taining inflammasome, followed by the activation of caspase-1 
(casp-1), cleavage of pro-IL-1β, and release of bioactive IL-1β (2). 
Mechanisms controlling ATP-induced inflammasome activation 
are in the focus of medical research because of their eminent 
relevance for the control of SIRS and sepsis.
Increasing evidence suggests that alpha-1 antitrypsin (AAT; 
synonym serine protease inhibitor, clade A, member 1, SERPINA1) 
interferes with the production of IL-1β and other pro-inflamma-
tory cytokines (3–8), independent of its well-known function 
as a major inhibitor of proteases including neutrophil elastase 
(NE), proteinase 3, and chymase (4). During systemic inflam-
mation, AAT synthesis is upregulated in the liver in response to 
circulating IL-6-type cytokines that are typically induced by IL-1β 
(4). Monocytes, macrophages, and dendritic cells are additional 
sources of AAT, albeit—in comparison to the liver—only small 
amounts are produced (9).
Under physiological conditions, plasma concentrations of 
AAT range from 0.9 to 2 mg/ml and a threefold to fourfold increase 
is typically measured during inflammation (4). Individuals 
with plasma AAT values below 0.7 mg/ml are considered to be 
AAT-deficient and have an increased risk for early-onset lung 
emphysema, liver disease and, in rare cases, vasculitis, asthma, 
and panniculitis (4). AAT infusions (e.g., Prolastin®) were 
approved for maintenance therapy of AAT-deficient patients 
suffering from emphysema and are generally well tolerated, but 
the efficiency of this treatment regarding emphysema is at best 
mediocre (10). By contrast, AAT therapy seems to be very effec-
tive in those AAT-deficient patients suffering from panniculitis, 
vasculitis, and asthma (5, 6), suggesting that AAT-mediated 
anti-inflammatory effects are most important.
Numerous studies on animal models of inflammatory disea ses 
that involve IL-1β underscore the immuno-modulatory potential 
of AAT (5–7). AAT protects from experimental ischemia-
reperfusion injury, rejection of islet  allografts, graft-versus-
host-disease, autoimmune arthritis, LPS-induced inflammation, 
and even exerts anti-bacterial effects (5–7). AAT has a strong, 
predominantly anti-inflammatory impact on the function of 
monocytes and neutrophils. It regulates chemotaxis, cell adhe-
sion as well as the expression of toll-like receptor 4, chemokines, 
and pro-inflammatory cytokines. Furthermore, AAT reduces the 
production of superoxide and nitric oxide, and upregulates anti-
inflammatory mediators (3, 4, 7). Nevertheless, the molecular 
mechanisms by which AAT modulates innate immunity are 
poorly understood.
Here, we test the hypothesis that ATP-dependent IL-1β release 
from blood leukocytes is regulated by AAT. We demonstrate that 
AAT activates a novel triple-membrane passing mechanism that 
inhibits ATP signaling and thereby, maturation and release of 
IL-1β by human blood leukocytes.
MaTerials anD MeThODs
reagents
Lipopolysaccharide (from E. coli, L2654), nigericin, BzATP, 
arachidonic acid (10931), cis-5,8,11,14,17-eicosapentaenoic acid 
(EPA, E2011), linoleic acid (LA, L1376), oleic acid (OA, O1008), 
mecamylamine hydrochloride, and strychnine hydrochloride 
were obtained from Sigma-Aldrich (Taufkirchen, Germany), 
thapsigargin, ATK, and BEL from Enzo Life Sciences (Lausen, 
Switzerland), α-bungarotoxin from Tocris Bioscience (Bristol, 
UK), and Prolastin® from Grifols (Frankfurt, Germany). 
Conotoxins RgIA4 and ArIB were described previously (11–13). 
Polyclonal goat-anti-AAT was purchased from Bethyl (A80-122A, 
Montgomery, AL, USA), monoclonal rabbit anti-CD36 antibod-
ies (clone D8L9T) from Cell Signaling Technologies (Danvers, 
MA, USA), and mouse anti-β-actin antibodies (clone A2228) 
from Sigma-Aldrich. Horseradish peroxidase-labeled secondary 
antibodies, rabbit anti-mouse Ig, rabbit anti-goat Ig, and goat 
anti-rabbit Ig, were provided by Dako (Glostrup, Denmark). The 
C-terminal peptide of AAT (C-36, corresponding to residues 
359–394) was synthesized by JPT Peptide Technologies GmbH 
(Berlin, Germany) and provided with a purity of >95% (HPLC).
Purification of aaT
Human plasma was obtained from healthy male non-smoking 
volunteers as approved by the local ethics committee of the 
University of Giessen (No. 81/13). AAT was isolated by affinity 
purification using Alpha1 Antitrypsin Select from GE Healthcare 
Europe (Freiburg, Germany) and Polyprep chromatography col-
umns from Bio-Rad (Munich, Germany) essentially as described 
by the supplier followed by a buffer exchange to PBS using 
Amicon® Ultra Centrifugal Filters with a cut-off of 10 kDa (Merck-
Millipore, Darmstadt, Germany). The quality and efficiency of the 
purification was controlled by SDS-PAGE (7.5% acrylamide) and 
Brilliant Blue staining. To test for the anti-protease activity, puri-
fied AAT was incubated with NE (Merck-Millipore) at a 1:2 M 
ratio in 100 mM Tris/HCl pH 7.4 for 30 min at 37°C. Thereafter, 
the reaction was stopped by boiling in SDS-sample buffers and 
the samples were separated by SDS-PAGE.
Oxidation of aaT
Oxidized AAT (oxAAT) was prepared as previously described 
(14). Briefly, N-chlorosuccinimide (Sigma-Aldrich) was added 
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to AAT protein at a molar ratio of 25:1, incubated for 30 min 
at room temperature, and excess of N-chlorosuccinimide was 
removed by ultrafiltration. The quality of oxidation was con-
trolled by testing anti-elastase activity. Native or oxAAT was 
pre-incubated with NE (at a molar ratio of 1.5:1) for 30  min. 
Thereafter, samples were analyzed by SDS-PAGE in 7.5% poly-
acrylamide gels followed by staining with Brilliant Blue.
U937 cells
U937 cells (German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany) were kept in RPMI 1640 
medium (Gibco, Thermo Fisher Scientific, Rockford, IL, USA) 
at 37°C and 5% CO2. Medium was supplemented with 10% fetal 
bovine serum (FBS Superior, Biochrom, Berlin, Germany) and 
2  mM glutamin (Glutamax®, Gibco). Cells were primed with 
LPS (1 µg/ml) for 5 h and incubated with BzATP (100 µM) or 
nigericin (1–50 µM) for 30 min. In some experiments, nigericin 
was applied together with apyrase (0.5  U/ml, A6410, Sigma-
Aldrich) to eliminate endogenous ATP. AAT and further reagents 
were applied together with BzATP. Supernatants were collected 
and stored at −20°C until measurement of IL-1β and lactate 
dehydrogenase (LDH).
human leukocytes
The use of blood from healthy male non-smoking volunteers 
was approved by the local ethics committee of the University 
of Giessen (No. 81/13). Peripheral blood mononuclear cells 
(PBMC) were isolated by density gradient centrifugation 
using Leucosep gradients (Greiner Bio-One, Frickenhausen, 
Germany). CD14+ monocytes were enriched by positive selec-
tion using Dynabeads® CD14 (Invitrogen, Karlsruhe, Germany) 
according to the instructions of the suppliers. Cell preparations 
were evaluated by flow cytometry (FACSCaliburTM, Becton 
Dickinson, San Jose, CA, USA) using FITC-labeled monoclonal 
antibody M5E2 to CD14 (BioLegend, San Diego, CA, USA). 
Monocyte purity was above 75%. Cells were cultured for 3 h and 
stimulated with BzATP as described previously (15) and AAT-P 
(1 mg/ml) was applied together with BzATP.
Mouse PBMc
Breeding of calcium-independent phospholipase A2β (iPLA2β) 
gene-deficient mice (iPLA2β−/−) was performed at the animal 
facility of the University Heidelberg as described previously (16). 
Wild type (WT) C57/BL6 mice were purchased from Janvier Labs 
(Le Genest St. Isle, France). All experimental animals received 
humane care according to NIH “Guide for the Care and Use of 
Laboratory Animals.” Animal experiments were approved by 
the local committee at the Regierungspräsidium Giessen, Hesse, 
Germany (permit no. 571_M) and the Regierungspräsidium 
Karlsruhe, Baden-Württemberg, Germany (permit no. G248/11). 
PBMC isolation from female mice, culturing, and stimulation 
were performed as described previously (12).
rat Precision cut lung slices (Pcls)
Female rats (Wistar WU, 10–12  weeks) were obtained from 
Charles River (Sulzfeld, Germany). Animals were kept under 
conventional housing conditions (22°C, 55% humidity, 12-h 
day/night rhythm). Rats were sacrificed by i.p. injection of an 
overdose of pentorbarbital sodium (Narkoren®, Merial GmbH, 
Hallbergmoos, Germany). Rat lungs were harvested, filled ex 
situ with 37°C warm 1.5% (wt/vol) low-melting agarose/DMEM 
solution and cooled in ice-cold DPBS after instillation. After 
preparation of cylindrical tissue cores (8  mm diameter), tissue 
was processed into approximately 300  µm thick slices with a 
Krumdieck tissue slicer (Alabama Research and Development, 
Munford, AL, USA). After washing of the slices, two PCLS were 
cultivated per well and stimulated with LPS (100  ng/ml) for 
23.5 h. 30 min prior to collecting the supernatants, the slices were 
additionally treated with BzATP (150 µM). AAT-P (1 mg/ml) was 
applied together with BzATP.
elisa
Interleukin-1β concentrations were measured in cell culture 
supernatants by Human IL-1beta DuoSet (R&D systems, 
Minneapolis, MN, USA) combined with DuoSet ancillary 
kit (R&D systems) according to manufacturer’s instructions. 
Ana lo gously, rat IL-1β concentrations were quantified in tissue 
culture supernatants by Rat IL-1β/IL-1F2 DuoSet (R&D systems, 
Minneapolis, MN, USA) and mouse IL-1β concentrations were 
measured in cell culture supernatants by using mouse Quantikine 
IL-1β Immunoassay (R&D Systems) according to manufacturer’s 
instructions. Measured cytokines released by PCLS were normal-
ized against the total protein content of the tissue slices, assessed 
through a BCA protein assay kit (Pierce Biotechnology, Rockford, 
IL, USA).
cell Viability
Cell viability was assessed by measurement of LDH concentra-
tions in cell culture supernatants. Supernatants were analyzed 
with CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, 
Madison, WI, USA). LDH release of ex vivo rat lung tissue was 
measured with a Cytotoxicity Detection Kit (Roche, Mannheim, 
Germany). Maximal LDH release was assessed by lysing the tissue 
slices with 1% Triton X-100 in DPBS (Lonza, Verviers, Belgium) 
at 4°C for 1 h.
gene silencing
To silence the expression of CD36 and iPLA2β in U937 cells, 
Amaxa Cell Line Nucleofactor Kit C and Nucleofactor II Device 
(both from Lonza Cologne, Cologne, Germany) were used. Cells 
were transfected with ON-TARGETplus SMARTpool siRNA 
targeting human CD36 and iPLA2β (CD36 and PLA2G6), 
as well as with Non-targeting Control Pool (Thermo Fisher 
Scientific, Schwerte, Germany) at a concentration of 30 pM 
siRNA/1 × 106 cells.
co-immunoprecipitation
Lipopolysaccharide-primed U937 cells (25  ×  106/ml) were 
lysed with agitation on ice for 30 min in 25 mM HEPES pH 7.2, 
1 mM CaCl2, 1 mM MgCl2, 1% Triton-X100 supplemented with 
protease and phosphatase inhibitor (tablets from Thermo Fisher 
Scientific) and centrifuged. 500 µg AAT-P was loaded on 200 µl 
of Alpha1 Antitrypsin Select (GE Healthcare) incubated with the 
supernatant of the lysate over night at 4°C. In controls, AAT-P 
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was omitted. After incubation, Alpha1 Antitrypsin Select beads 
were washed with lysis buffer, bound complexes were eluted as 
indicated by the supplier, mixed with concentrated SDS sample 
buffer, and subject to Western blotting.
sDs-Page and Western Blotting
U937 cells were lysed and the protein concentration was assessed 
using a BCA protein assay kit (Pierce Biotechnology, Rockford, 
IL, USA). 10  µg of protein per sample was fractionated by 
SDS-PAGE on 10% gels and transferred to Immobilon poly-
vinylidene difluoride membranes (Millipore, Billerica). Dual 
color precision plus protein standards (Bio-Rad, Hercules, CA, 
USA) were used as molecular weight markers. Membranes were 
blocked with Roti®-Block (Roth, Karlsruhe, Germany) (CD36), 
5% low-fat milk powder (Roth) (β-actin) or 5% BSA (AAT) in 
PBS and incubated with primary antibodies (anti-AAT 1:20,000, 
anti-CD36 1:1,000, β-actin 1:50,000) in blocking solution. PBS 
supplemented with 0.01% Tween-20 was used for washing 
steps and appropriate secondary antibodies (1:5,000 each) were 
diluted in PBS, 0.01% Tween-20, 2.5% low-fat milk powder. 
SuperSignal West Dura Extended Duration Substrate (Thermo 
Fisher Scientific) was used for the detection of CD36, blots 
were developed using Lumi-Light substrate (Roche, Mannheim, 
Germany) to visualize β-actin and documented with High 
Performance Chemiluminescence Films (GE Healthcare).
sera From Type i cD36-Deficient Patients
Sera from CD36 type I-deficient patients were collected from 
healthy blood donors, mothers with fetal/neonatal alloimmune 
thrombocytopenia and platelet transfusion refractoriness by 
Guangzhou Blood Center, Guangzhou, China. The presence of 
anti-CD36 antibodies in these sera and the absence of CD36 
expression on monocytes and platelets were confirmed by flow 
cytometry and nucleotide sequencing analysis. The collection and 
the use of these sera for research were approved by Guangzhou 
Ethics Committee for human research (GZBC-EA-2016-010), 
and all patients gave written informed consent.
Patch-clamp experiments
Whole-cell patch-clamp recordings on U937 cells where essen-
tially performed as described previously (15). AAT-P and meca-
mylamine were used at concentrations of 1 mg/ml and 100 µM, 
respectively.
Ultrafiltration of cell culture supernatants
U937 cells were primed with LPS as described above but in the 
absence of FBS and stimulated with AAT-P (1 mg/ml). Thereafter, 
the cell-free supernatant was ultrafiltrated using Amicon® Ultra 
Centrifugal Filters with a cut-off of 10  kDa. The resulting low 
molecular mass fraction was applied at different concentrations 
to another set of LPS-primed U937 cells shortly before stimula-
tion with BzATP.
statistics
Statistical analyses were performed using SPPS® (Version 23, 
IBM®, Armonk, NY, USA). Multiple data groups were first 
analyzed using Kruskal–Wallis test followed by two-tailed 
Mann–Whitney rank sum test. Data on primary cells were analyzed 
using Wilcoxon signed-rank test. IC50 values were deter mined 
using GraphPad Prism® (Version 6, GaphPad Software) by 
fitting log-transformed concentration values and the original 
effect data.
resUlTs
aaT inhibits the aTP-Dependent release 
of il-1β
Human monocytic U937 cells were primed with LPS for 
5  h, followed by application of 2′(3′)-O-(4-Benzoylbenzoyl)
adenosine-5′-triphosphate (BzATP), an analog of ATP that 
preferentially activates the P2X7R. In line with our hypothesis, 
the preparation of human plasma AAT (Prolastin®, AAT-P) 
efficiently and dose-dependently inhibited the expected 
BzATP-induced release of IL-1β to the cell culture supernatant 
(IC50 0.2  mg/ml; Figure  1A). Of note, typical AAT blood 
concentrations of healthy humans (0.9–2  mg/ml) are suf-
ficient to completely suppress IL-1β release from U937 cells. 
The inhibitory effect of AAT-P was corroborated with AAT 
isolated from the blood of healthy donors (IC50 0.1  mg/ml; 
Figure 1B). SDS-gel electrophoresis of these AAT preparations 
revealed one major band with an apparent molecular mass of 
about 52  kDa (Figure  1C). The anti-protease activity of the 
AAT from healthy donors was confirmed by complex (77 kDa) 
formation with NE (Figure 1C). Previous studies have shown 
that anti-inflammatory functions of AAT can be independent 
of its anti-protease activity (7). In the same line, oxAAT, which 
is devoid of anti-elastase activity, efficiently inhibited BzATP-
induced IL-1β release by LPS-primed U937 cells (IC50 0.05 mg/
ml; Figures 1D,E). Cell death as measured by LDH activity in 
the supernatant was not affected by BzATP or AAT in these and 
in all following experimental settings. We selected AAT-P at a 
concentration of 1 mg/ml for most experiments of this study.
Next, we investigated PMMC and enriched primary mono-
cytes from healthy human volunteers, in which isolation and cul-
ture already induces pro-IL-1β expression (15). AAT-P (1 mg/ml) 
significantly (p = 0.031, n = 6 each) reduced the BzATP-induced 
release of IL-1β from these cells to about 50% (Figures 1F,G).
We studied LPS-primed rat PCLS, an established ex vivo 
model for pulmonary inflammation (17). AAT-P (1 mg/ml) fully 
inhibited the BzATP-induced IL-1β release (p =  0.029, n =  4, 
Figure 1H). We suggest that—in line with our hypothesis—AAT 
is a strong inhibitor of ATP-induced IL-1β release by human 
PBMC as well as by rat lung tissue.
aaT Does not impair nigericin-Dependent 
il-1β release
Nigericin is a bacterial pore-forming toxin that enables trans-
membrane potassium efflux, assembly of the NLRP3 inflamma-
some, and activation of casp-1 independent of ATP (2). 50 µM 
nigericin was needed to induce a significant release of IL-1β 
within 30  min of incubation (p =  0.029, n =  4) (Figure  2A). 
At all concentrations, the amount of LDH released to the super-
natant was unchanged. To test if AAT inhibits ATP-independent 
A B
C D E
F G H
FigUre 1 | Continued
5
Siebers et al. AAT Inhibits IL-1β Release
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 877
pathways of NLRP3 inflammasome activation, LPS-primed 
U937 cells were stimulated with nigericin (50  µM). In these 
experiments, the ATP degrading enzyme apyrase (0.5 U/ml) was 
added. We rejected the hypothesis that AAT directly inhibits 
casp-1, as AAT-P (1 mg/ml) did not impair the nigericin-induced 
release of IL-1β from LPS-primed U937 cells (n = 4; Figure 2B).
A B
FigUre 2 | Alpha-1 antitrypsin (AAT) does not inhibit the nigericin-induced release of interleukin (IL)-1β. Human lipopolysaccharide (LPS)-primed monocytic U937 
cells were stimulated with different concentrations of nigericin (1–50 µM) in the absence (a) or presence (B) of apyrase (0.5 U/ml) and of the AAT preparation 
Prolastin® (AAT-P) (1 mg/ml). IL-1β released to the supernatant was measured after 30 min. Data are presented as individual data points, bar represents median, 
whiskers encompass the 25th to 75th percentile, n-numbers of independent experiments are indicated in the figure. Experimental groups were compared by 
Kruskal–Wallis test followed by Mann–Whitney rank sum test.
FigUre 1 | Native and oxidized alpha-1 antitrypsin (AAT) inhibit the ATP-dependent release of interleukin (IL)-1β. (a,B,D) Human lipopolysaccharide (LPS)-primed 
monocytic U937 cells were stimulated with 2′(3′)-O-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP, 100 µM) in the presence or absence of different 
concentrations of the AAT preparation Prolastin® [(a) AAT-P], of native AAT purified from the blood of healthy donors (B) and of oxidized AAT (oxAAT) (D). IL-1β 
released to the supernatant was measured after 30 min. Native (c) and oxAAT (e) were separated by SDS-polyacrylamide gel electrophoresis (7.5% acrylamide) 
and stained with Brilliant Blue. In addition, native AAT from healthy donors (D1–D4) and oAAT were incubated with neutrophil elastase (NE) before electrophoresis. 
Arrows are pointing to NE (25 kDa), a fragment of AAT (48 kDa), AAT (52 kDa), oxAAT (52 kDa), and to a covalent complex of cleaved AAT and NE (77 kDa). (F,g) 
BzATP-mediated release of IL-1β from freshly isolated peripheral blood mononuclear cells (F) or enriched monocytes (g) from healthy human donors in the presence 
or absence of AAT-P (1 mg/ml). Absolute IL-1β values obtained from individual donors are connected by lines. (h) Rat precision cut lung slices were primed with 
LPS followed by application of BzATP in the presence or absence of AAT-P (1 mg/ml). Data are expressed as the concentration of IL-1β released per milligram lung 
tissue protein. Data are presented as individual data points, bar represents median, whiskers encompass the 25th to 75th percentile, n-numbers of independent 
experiments are indicated in the figure. Experimental groups were compared by Wilcoxon signed-rank test (F,g) or Kruskal–Wallis test followed by Mann–Whitney 
rank sum test (a,B,D,h) (*p ≤ 0.05 compared to supernatants from cells treated with LPS and BzATP alone).
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aaT signals via cD36
CD36, a lipid scavenger receptor and taste receptor of long chain 
fatty acids (18), was shown before to interact with a fragment of 
AAT (19). Therefore, we studied its involvement in the signaling 
of AAT. CD36 expression was successfully silenced in U937 cells 
by siRNA (n = 4, p = 0.029; Figure 3A). In comparison to U937 
cells treated with control siRNA, CD36 silencing significantly 
blunted the inhibitory effect of AAT-P on the BzATP-induced 
IL-1β release from LPS-primed U937 cells (n =  5, p =  0.016; 
Figure  3B). To corroborate the involvement of CD36 in AAT 
signaling, we used sera from type I CD36-deficient individuals 
who developed antibodies against CD36 during pregnancies 
or due to incompatible platelet transfusions. Recently, CD36 
expression in these patients was carefully analyzed by flow 
cytometry, the CD36 genes were sequenced, and the presence 
of anti-CD36 antibodies in the serum was verified (20, 21). 
These sera dose-dependently antagonized the inhibitory effect 
of AAT-P, whereas sera from healthy blood donors did not 
(Figures 3C,D). Of note, neither control sera nor sera contain-
ing anti-CD36 antibodies provoked the release of IL-1β in the 
absence of BzATP (Figures  3C,D). In line with these results, 
co-immunoprecipitation experiments suggested that CD36 and 
AAT-P can physically interact (Figure 3E). In conclusion, our 
data are in line with the hypothesis that AAT-P signals via CD36 
to inhibit BzATP-induced release of IL-1β.
Do other ligands of CD36 also inhibit the ATP-induced 
release of monocytic IL-1β? Previously, we demonstrated that 
phosphatidylserine, another ligand of CD36 (22) does not 
inhibit the release of IL-1β in the same experimental setting 
(23). In the same line, LA (2  mM, n =  4) and OA (2  mM, 
n = 4) did not impair the BzATP-induced release of IL-1β by 
LPS-primed U937 cells (Figure 3F). These free long chain fatty 
acids are also known ligands of CD36 (24). In addition, pilot 
experiments suggested that the CD36-ligands arachidonic acid 
(25) (0.1–1,000  µM, n =  2 each), EPA (24) (40  µM, n =  2), 
and C-36, the C-terminal peptide fragment of AAT (19) 
(1 µg/ml–2 mg/ml, n = 2 each), are also inactive in this experi-
mental setting.
aaT signaling activates iPla2β
Ligand binding to CD36 can induce activation of members of 
the phospholipase A2 (PLA2) family (18, 26). To test if PLA2 
A B
C D
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FigUre 3 | Continued
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activation can inhibit IL-1β release from U937 cells, we first used 
thapsigargin, a blocker of sarcoplasmic-endoplasmic Ca2+-ATPase 
(SERCA) that activates PLA2 in the context of store-operated 
calcium reentry. In line with our hypothesis, thapsigargin dose-
dependently and efficiently inhibited BzATP-induced release of 
IL-1β from LPS-primed U937 cells (Figure 4A).
FigUre 3 | Alpha-1 antitrypsin (AAT) signaling involves CD36. (a,B) Expression of CD36 by U937 cells was silenced using siRNA (si CD36, n = 4). Another set of 
cells was transfected with control siRNA (si con, n = 4). (a) Cell extracts were separated by SDS-polyacrylamide gel electrophoresis (10% acrylamide) along with 
molecular weight markers. CD36 and β-actin protein expression were evaluated by Western blotting followed by densitometry. The ratio of the optical density (OD)  
of CD36- and β-actin-immunopositive bands was formed, normalized to the values obtained for si con-transfected cells and expressed as arbitrary units (AU).  
(B) U937 cells were transfected with si con or with si CD36, primed with lipopolysaccharide (LPS) and release of interleukin (IL)-1β was stimulated with 2′(3′)-O- 
(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP, 100 µM) in the presence or absence of the AAT preparation Prolastin® (AAT-P, 1 mg/ml). (c,D) LPS-primed 
U937 cells were stimulated with BzATP in the presence of AAT-P and different concentrations of serum containing antibodies to CD36 (c) and control serum from 
healthy human donors (D). (e) AAT (Prolastin®) was added to lysates of LPS-primed U937 cells and immunoprecipitated. Co-immunoprecipitation of CD36 was 
visualized Western blotting using antibodies to CD36, precipitation of AAT using antibodies to AAT. In controls (con), no AAT was added to the lysate. (F) LPS-
primed U937 cells were stimulated with BzATP in the presence or absence of linoleic acid (LA, 2 mM) or oleic acid (OA, 2 mM). (a–D,F) Data are presented as 
individual data points, bar represents median, whiskers encompass the 25th to 75th percentile, n-numbers of independent experiments are indicated in the  
figure. Experimental groups were compared by Kruskal–Wallis where applicable (B–D), followed by Mann–Whitney rank sum test (a–D) (*p ≤ 0.05; **p ≤ 0.01 
compared to supernatants from cells treated with LPS, BzATP, and AAT-P).
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This prompted us to investigate if PLA2 is involved in sign-
aling of AAT-P. We used arachidonyl trifluoromethyl ketone 
(ATK, 50  µM) an inhibitor of both calcium-dependent PLA2 
and calcium-independent PLA2 (iPLA2), as well as bromoenol 
lactone (BEL, 50 µM), a preferential inhibitor of iPLA2β (syno-
nyms: group VIA iPLA2, iPLA2b, or PLA2G6). The inhibitory 
effect of AAT-P (1  mg/ml) on BzATP-induced IL-1β release 
was reversed by ATK (n =  4, p =  0.029; Figure  4B) and BEL 
(n = 4, p = 0.029; Figure 4C). We recently demonstrated in the 
same experimental setting that transfection of U937 cells with 
siRNA specific for iPLA2β resulted in a reduced expression of 
iPLA2β protein in comparison to cells transfected with control 
siRNA (27). Silencing of iPLA2β expression but not transfec-
tion of control siRNA significantly blunted the effect of AAT-P 
(1 mg/ml) in U937 cells (n = 4, p = 0.029; Figure 4D).
In an independent approach, we analyzed adherent PBMC 
from WT and iPLA2β gene-deficient mice (16). While AAT-P 
(1 mg/ml) efficiently inhibited BzATP-induced IL-1β release in 
WT PBMC, iPLA2β gene-deficient PBMC released a slightly 
higher amount of IL-1β in the presence of AAT-P (n = 4, p = 0.029; 
Figure 4E). Our results demonstrate that human AAT-P is equally 
active in mice and further support the hypothesis that iPLA2β is 
involved in signaling of AAT.
aaT signaling involves nicotinic 
acetylcholine receptors (nachr)
Next, we investigated if AAT-P signals via nAChR using a set 
of nAChR antagonists at commonly used concentrations. 
Mecamylamine (100  µM), an unselective nicotinic antagonist, 
α-bungarotoxin (1  µM) and strychnine (10  µM), two antago-
nists of nAChR containing subunits α7 and α9, were applied to 
LPS-primed U937 cells shortly before application of AAT-P and 
BzATP. The inhibitory effect of AAT-P on the BzATP-induced 
release of IL-1β was sensitive to all three nicotinic antagonists 
(n = 4 versus 5, p = 0.016; Figure 5A). None of these antagonists 
induced IL-1β release when applied alone (data not shown). To 
differentiate between nAChR composed of subunits α7 and of 
α9α10, we used the α-conotoxin ArIB [V11L, V16D] (500 nM) 
that is a specific antagonist of receptors containing the α7 subunit 
and the α-conotoxin RgIA4 (200  nM), specific for α9 and α10 
(11–13). ArIB was ineffective but RgIA4 fully reversed the effect 
of AAT-P (n = 4 versus 5, p = 0.016; Figure 5A), suggesting that 
α9 and/or α10 nAChR subunits are indispensable for the signal-
ing of AAT.
To further dissect the involvement of nAChR subunits in 
AAT-P signaling, subunits α7, α9, and α10 in U937 cells were 
silenced by siRNA. Due to a lack of specific antibodies to nAChR 
subunits α7, α9, and α10, we could not monitor protein expres-
sion. The efficiency and specificity of gene-silencing in U937 cells 
was shown recently by our group in the same experimental set-
ting for subunits α9 and α10 on the mRNA level (15). The mRNA 
expression of subunit α7, however, was too low for quantifica-
tion. Transfection with siRNA targeting subunit α9 slightly but 
significantly impaired the effect of AAT-P on the BzATP-induced 
release of IL-1β (n = 6 versus n = 8, p = 0.0007), whereas single 
silencing of subunits α7 or α10 did not (Figure 5B). After double 
knockdown of combinations of α7, α9, or α10, AAT-P signaling 
was significantly blunted, in each receptor subunit combination 
(n =  4 each, p =  0.029; Figure  5C). These results suggest that 
nAChR subunits α7, α9, and α10 contribute to AAT-P signaling 
and that the concomitant function of at least two of them is 
mandatory. Single knockdown experiments suggest that subunit 
α9 might be more important than subunits α7 and α10.
aaT signaling inhibits P2X7r
To test if the ATP-induced P2X7R activation is affected by 
AAT, patch-clamp experiments were performed on LPS-primed 
U937 cells. Application of BzATP induced ion currents, which 
were repeatable without obvious desensitization Figures 5D,E. 
BzATP was first applied alone, followed by application of 
AAT-P (1  mg/ml), which did not change ion currents by 
itself Figures 5D,E. When BzATP was applied in the presence 
of AAT-P, no changes of ion currents were detected (n =  6, 
p =  0.028; Figures  5D,E). The inhibitory effect of AAT-P on 
BzATP-induced ion channel function was fully antagonized 
in the presence of mecamylamine (100  µM) confirming the 
involvement of metabotropic nAChR functions in the AAT-P-
mediated signaling (Figures 5D,E). These data are in line with 
the hypothesis that AAT-P inhibits BzATP-dependent P2X7R 
functions, an essential step in ATP-dependent inflammasome 
activation.
aaT-P Triggers the release of a nicotinic 
agonist
Finally, we wondered how AAT signaling via CD36 and iPLA2β 
links to the activation of nAChR. We demonstrated before 
that compounds with a phosphocholine head group includ-
ing lysophosphatidylcholines function as unconventional 
A B
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FigUre 4 | Alpha-1 antitrypsin (AAT) signaling involves activation of calcium-independent phospholipase A2β (iPLA2β). (a–D) Lipopolysaccharide (LPS)-primed 
U937 cells were stimulated with 2′(3′)-O-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP) in the presence or absence of Prolastin® (AAT-P, 1 mg/ml). Interleukin 
(IL)-1β released to the supernatant was measured after 30 min. Different doses of thapsigargin (a), the unselective PLA2 inhibitor arachidonyl trifluoromethyl ketone 
[ATK, (B)] or the preferential iPLA2β inhibitor bromoenol lactone [BEL, (c)] were added together with BzATP and AAT-P. (D) Expression of iPLA2β by U937 cells was 
silenced by siRNA (si iPLA2β). In addition, cells were transfected with control siRNA (si con). U937 cells transfected with si con or with si iPLA2β were primed with 
LPS and the release of IL-1β was stimulated by BzATP. (e) Adherent peripheral blood mononuclear cells were isolated from wild type (WT) or iPLA2β gene-deficient 
mice (iPLA2β−/−) and stimulated with BzATP in the absence or presence of AAT-P. IL-1β released in response to BzATP was normalized to 100%. Data are presented 
as individual data points, bar represents median, whiskers encompass the 25th to 75th percentile, n-numbers of independent experiments are indicated in the 
figure. Experimental groups were compared by Kruskal–Wallis test followed by Mann–Whitney rank sum test.
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nicotinic agonists that inhibit the ion channel function of 
P2X7R in human monocytic cells (12, 15, 23, 28). As iPLA2β 
has the capacity to cleave phosphatidylcholines to free fatty 
acids and lysophosphatidylcholines, we hypothesized that 
AAT-P triggers the release of a bioactive factor that medi-
ates the cholinergic inhibition of P2X7R and IL-1β release. 
A B
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FigUre 5 | Alpha-1 antitrypsin (AAT) signaling involves nicotinic acetylcholine receptors (nAChR) and inhibits P2X7 receptor function. Lipopolysaccharide 
(LPS)-primed U937 cells were stimulated with 2′(3′)-O-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP) in the presence or absence of Prolastin® (AAT-P,  
1 mg/ml). (a–c) Interleukin (IL)-1β released to the supernatant was measured after 30 min. (a) Nicotinic antagonists mecamylamine (Mec), α-bungarotoxin  
(α-Bun), strychnine (Stry), RgIA4, or ArIB [V11L, V16D] were added together with BzATP and AAT-P, *p ≤ 0.05 compared to cells treated with LPS, BzATP, and 
AAT-P. (B,c) Expression of nAChR subunits α7, α9, and α10 was silenced by siRNA (si α7, α9, α10). Cells were either transfected with a single siRNA (B) or with  
a combination of two of them (c). In addition, cells were transfected with control siRNA (si con); *p ≤ 0.05, compared to data from respective experiments on cells 
treated with si con. (c). (D,e) Whole-cell patch-clamp experiments were performed on LPS-primed U937 cells stimulated with BzATP. Patch-clamp recordings of 
U937 cells are depicted in (D), and changes in ion currents (ΔI) are summarized in (e). BzATP was applied twice (I and II). The second BzATP stimulus was given in 
the presence or absence of AAT-P and Mec. Data are presented as individual data points, bar represents median, whiskers encompass the 25th to 75th percentile, 
n-numbers of independent experiments are indicated in the figure. Experimental groups were compared by Wilcoxon signed-rank test (e) or by Kruskal–Wallis 
followed by Mann–Whitney rank sum test (a–c).
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LPS-primed U937 cells were treated with AAT-P (1  mg/ml), 
the cell culture supernatant was harvested 30  min later and 
ultrafiltrated at a cut-off of 10 kDa to remove AAT-P with a 
molecular mass of about 52 kDa (Figure 6A). Control super-
natant was harvested from LPS-primed U937 cells in the same 
way but in the absence of AAT-P (control 1), or AAT-P was 
A B
C
FigUre 6 | Alpha-1 antitrypsin (AAT) induces the release of a bioactive factor. U937 cells were primed with lipopolysaccharide (LPS) and stimulated with Prolastin® 
(AAT-P 1 mg/ml) for 30 min before collection of the cell-free cell culture supernatant (SN). A low molecular mass fraction (LF) and a high molecular mass fraction (HF) 
of the cell culture supernatant were separated by ultrafiltration with a cut-off of 10 kDa. For the production of control LF, either no AAT-P was added to LPS-primed 
U937 cells (LF C1) or AAT-P was added to the cell-free cell culture supernatant (LF C2) shortly before ultrafiltration. (a) The SN, the LF, and the HF were separated  
in a 15% SDS-polyacrylamide gel along with a molecular mass marker followed by staining with Brilliant Blue. Bands with a molecular mass of about 52 kDa 
correspond to AAT. (B,c) LPS-primed U937 cells were stimulated with 2′(3′)-O-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP) in the presence or absence  
of AAT-P. The experiments were performed in medium, LF C1, LF C2, or in different concentrations of LF diluted in medium. Interleukin (IL)-1β released to the 
supernatant was measured after 30 min. (c) Nicotinic receptor antagonists mecamylamine (Mec), α-bungarotoxin (α-Bun), strychnine (Stry), RgIA4, or ArIB [V11L, 
V16D] were added together with BzATP in the presence of LF. *p ≤ 0.05 versus cells treated with LPS, BzATP, and AAT-P (B) or LF (c). Data are presented as 
individual data points, bar represents median, whiskers encompass the 25th to 75th percentile, n-numbers of independent experiments are indicated in the figure. 
Experimental groups were compared by Kruskal–Wallis followed by Mann–Whitney rank sum test (B,c).
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added to the cell-free supernatant shortly before ultrafiltration 
(control 2). Low molecular weight fractions were applied to 
another set of LPS-primed U937 cells together with BzATP and 
the release of IL-1β was measured 30 min later. In agreement 
with our prediction, the low molecular weight fraction dose-
dependently inhibited BzATP-induced IL-1β release, whereas 
this activity was absent in controls 1 and 2 (Figure 6B). The 
inhibitory activity was sensitive to the same panel of nAChR 
antagonists like AAT-P (n =  4 each, p =  0.029; Figures  5A  
and 6C). We conclude that a low molecular weight compound 
is released from U937 cells in response to AAT-P that activates 
nAChR of U937 cells.
DiscUssiOn
Alpha-1 antitrypsin is known to play an important protective 
anti-inflammatory role in vivo (3–7), but the underlying molecu-
lar mechanisms are poorly understood. Here, we demonstrate 
that physiological concentrations of AAT efficiently and dose-
dependently inhibit the ATP-induced IL-1β release by monocytic 
U937 cells, PBMC, and lung tissue. The commercially available 
AAT preparation Prolastin®, AAT freshly isolated from the blood 
of healthy donors and oxAAT are active. We provide evidence 
for a triple-membrane passing signaling mechanism of AAT 
that is summarized in Figure 7. AAT seems to signal via CD36, 
FigUre 7 | Suggested signaling mechanism of the alpha-1 antitrypsin 
(AAT)-induced control of ATP-induced inflammasome activation. Our results 
are in line with the following hypotheses: AAT binds to CD36 and induces 
activation of calcium-independent phospholipase A2β (iPLA2β), which 
cleaves membrane lipids and forms a yet unknown low molecular weight 
factor, presumably a cholinergic agonist. This agonist is released, activates 
nicotinic acetylcholine receptors (nAChR) containing subunits α9, α10, and/or 
α7 and inhibits the signaling of the ATP-sensitive P2X7 receptor. Our data 
suggest that AAT prevents inflammasome assembly, activation of caspase-1 
(casp-1), and release of interleukin (IL)-1β. Red arrows symbolize 
mechanisms that were investigated in this study.
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followed by activation of iPLA2β and release of a low molecular 
weight factor with cholinergic activity. Stimulation of nAChR, in 
turn, inhibits the ATP-gated ion channel function of the P2X7R 
and, hence, ATP-induced maturation and release of IL-1β. The 
experimental settings used in this study induce IL-1β secretion 
independent of cell death, as the LDH content of the cell culture 
medium was not increased. It was shown before that under these 
conditions, U937 cells and primary human blood leukocytes do 
not release IL-18 (15, 29).
Most experiments of this study were performed on human 
U937 cells, a monocytic cell line that produces only low amounts 
of IL-1β (12, 15, 23, 27, 28). As cell lines do not reflect all proper-
ties of primary cells, we included several well-validated primary 
cell and tissue culture models for inflammation. Experiments 
on human PBMC, enriched human monocytes, mouse PBMC, 
and rat PCLS clearly confirmed the data obtained from U937 
cells. We conclude that the AAT-mediated inhibition of ATP-
induced IL-1β is active in humans, mice, and rats. An efficient 
control of the release of monocytic IL-1β into the circulation 
seems to be mandatory, as cytokines are rapidly swept away 
from the site of inflammation and may cause life-threatening 
systemic inflammation. Because of the prominent role of AAT 
in the lung (4), we analyzed PCLS and demonstrated that AAT 
fully prevents the ATP-induced release of pulmonary IL-1β. 
The control of pulmonary inflammation is of outstanding 
importance, because on the delicate lung tissue is constantly 
exposed to environmental noxes that have to be efficiently 
cleared without inducing overt inflammation (30–32).
Exogenous AAT can enter the cytoplasm via lipid rafts (33) 
and was suggested to directly inhibit the proteolytic activity of 
casp-1 (34, 35). Although the inhibition of cytoplasmic casp-1 
of intact cells by AAT was disputed (36), we wondered if this 
mechanism is responsible for the AAT-mediated suppression of 
IL-1β release. This hypothesis was falsified by two independent 
experiments. First, IL-1β release triggered by nigericin, a pore-
forming bacterial toxin that stimulates casp-1 activation in an 
ATP-independent manner (37), is not impaired. Second, we 
demonstrated in patch-clamp experiments that AAT inhibits the 
ion channel function of the P2X7R, a mechanism that is upstream 
of NLRP3 inflammasome assembly and casp-1 activation (2).
A report on interactions of CD36 with the fibril-forming 
C-terminal C-36 fragment (C-36) of AAT prompted us to hypo-
thesize that CD36 is involved in AAT signaling (19). Indeed, 
CD36 gene-silencing significantly blunts the effect of AAT in our 
experimental setting. In the same line, sera from CD36-deficient 
patients who were sensitized to CD36 by blood transfusion or 
pregnancy (20, 21) dose-dependently reverse the inhibitory 
effect of AAT on the BzATP-induced release of IL-1β by U937 
cells, while control sera from healthy donors do not. In the same 
line, immunoprecipitation experiments suggested a physical 
interaction of CD36 and AAT in LPS-primed U937 cells. We 
suggest that CD36 is an essential part of the signaling cascade 
induced by AAT and that CD36 might function as a cellular 
receptor for AAT.
Our results seem to contradict studies that suggest a pro-
inflammatory role of CD36 (19, 38). CD36 contributes to cell 
priming via Toll-like receptors 4 and 6 and to inflammasome 
activation by promoting the cellular uptake of particle-forming 
matter such as oxidized LDL or amyloid-β (38). C-36 fragments 
interacting with CD36 and LDL receptors further stimulate 
of the uptake of oxidized LDL and induce the expression of 
pro-inflammatory cytokines IL-6 and monocyte chemoattract-
ant protein-1 (19). As CD36 is a versatile molecule that can 
function as a receptor mediating signal transduction or as a 
transmembrane transporter, the down-stream effects of CD36 
may be very different depending on the properties of the ligand 
and on the cell type investigated (25). In addition, we describe 
short-term effects (less than 30 min) of CD36 activation with 
AAT, whereas CD36-mediated expression of pro-inflammatory 
cytokines and inflammasome activation takes several hours 
(19, 38).
We reported before that the CD36 ligand phosphatidylserine 
does not inhibit the BzATP-induced release of IL-1β by LPS-
primed U937 cells (22, 23), and we provide similar data in the 
present study for LA and OA, other ligands of CD36 (25). These 
results suggest that the described down-stream effects leading to 
the inhibition of IL-1β release are rather specific for AAT and 
cannot be elicited by all known ligands of CD36. CD36 exerts 
numerous cell-specific functions as a lipid transporter, as a 
scavenger receptor and as a taste receptor for free long chain fatty 
acids (25). Accordingly, different isoforms of CD36 have been 
described that differ in posttranslational modifications such a 
differential glycosylation (25). With all due caution, we suggest 
that monocytic CD36 functions as a receptor of AAT.
As signal transduction via CD36 typically activates iPLA2β, 
a phospholipase that hydrolyzes the sn-2 acyl bond of phos-
phatidylcholines (18, 26), we hypothesized that activation of 
iPLA2β is an essential step in AAT signaling. In a first proof-of- 
principle experiment, we demonstrated that thapsigargin, an 
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inhibitor of Ca2+ reuptake by the endoplasmic reticulum and 
activator of iPLA2β (39), efficiently and dose-dependently 
inhibits the ATP-induced IL-1β release from LPS-primed U937 
cells. We demonstrate that the general PLA2 inhibitor ATK and 
the more specific iPLA2 inhibitor BEL fully abolish the effect 
of AAT on IL-1β release and gene-silencing results in a signifi-
cantly blunted effect of AAT. Furthermore, PBMC from iPLA2β 
gene-deficient mice are insensitive to AAT, whereas AAT almost 
fully abolishes the ATP-induced release of IL-1β by WT PBMC. 
We conclude from these data that iPLA2β is involved in the 
AAT-dependent signaling cascade that inhibits the ion channel 
function of P2X7R. A similar involvement of iPLA2β in the 
chemokine-dependent inhibition of IL-1β release was recently 
published by our group (27).
Activation of nAChR containing subunits α7, α9, and α10 
with canonical ligands such as acetylcholine or nicotine effi-
ciently suppresses BzATP-dependent ion currents and release of 
IL-1β from human monocytic cells (12, 15). We further identi-
fied phosphatidylcholines as well as their metabolites lysophos-
phatidylcholine, glyceophosphocholine, and phosphocholine 
as unconventional agonists of nAChR. These agonists inhibit 
P2X7R signaling in human monocytic cells but do not evoke 
ion currents at conventional nAChR (12, 23, 28). Interestingly, 
these unconventional nicotinic agonists slightly differed in their 
requirements for nAChR subunits. Signaling of phosphocholine 
depends on subunits α7, α9, and α10 (12, 15, 28), lysophos-
phatidylcholine and glycerophosphocholine depend on subunits 
α9 and α10, and dipalmitoylphosphatidylcholine depends on 
subunit α9 in combination with either subunit α7 or α10 (23, 28). 
As iPLA2β cleaves phosphatidylcholines and liberates lysophos-
phatidylcholines that can function as nicotinic agonists (28), we 
hypothesized that AAT induces the release of a factor that acts as 
an unconventional agonist of nAChR.
Signaling of AAT is indeed sensitive to the nictonic antagonists 
mecamylamine, strychnine, and α-bungarotoxin, suggesting 
that the evolutionary conserved family of nAChR comprising 
subunits α7, α9, and α10 is involved (40–42). Among them, 
subunits α9 or α10 seem to be mandatory, because the conotoxin 
RgIA4 fully inhibits the effect of AAT, while conotoxin ArIB is 
ineffective, suggesting that subunit α7 is dispensable (11–13, 43). 
The importance of subunit α9 is corroborated in gene-silencing 
experiments, whereas single knockdown of subunits α7 or α10 
has no effect. All combinations of double-knockdowns, how-
ever, lead to a blunted inhibitory effect of AAT. Taken together, 
nAChR subunit α9 seems to be mandatory but not sufficient for 
AAT signaling. In addition, either subunit α7 or subunit α10 are 
needed.
In line with numerous previous studies showing that nicotinic 
stimuli do not induce ion channel functions at leukocytic nAChR 
(12, 15, 44–48), AAT does not trigger ion currents in LPS-primed 
U937 cells. By contrast, BzATP provokes repeatable ion currents 
that are prevented in the presence of AAT. Also in this experi-
mental setting, the effects of AAT are sensitive to mecamylamine. 
These data suggest that much like nicotine, phosphocholine, 
glycerophosphocholine, palmitoyl-lysophosphatidylcholine, or 
dipalmitoylphosphatidylcholine (12, 15, 23, 28), AAT activates 
nAChR that inhibit the ion channel function of P2X7R.
Finally, we show that LPS-primed U937 cells release small 
bioactive molecules in response to AAT that efficiently and 
dose-dependently inhibit the BzATP-induced IL-1β release. The 
activity of these molecules is reversed by nAChR antagonists of 
subunits α9/α10 but not by the conotoxin ArIB, which is specific 
for subunit α7 (11–13). This sensitivity toward nAChR antago-
nists is the same for both, AAT and the small molecular weight 
factor released in response to AAT. Hence, we suggest that AAT 
induces the release of nicotinic agonists that mediate the activa-
tion of nAChR. We are currently trying to elucidate the chemical 
identity of the bioactive factor(s) that are released in response to 
AAT. As iPLA2β is involved in signaling, metabolites of phos-
phatidylcholines are plausible candidates. The free long-chain 
fatty acids tested in this study were inactive, but all compounds 
with a phosphocholine head group we investigated inhibited 
the BzATP-induced release of IL-1β (12, 15, 28). Therefore, 
we hypothesize that the active mediators are phosphocholine-
containing metabolites of phosphatidylcholines, but these are 
numerous and diverse.
Our current working hypothesis of the signaling cascade of 
AAT is depicted in Figure  7. We suggest a triple-membrane-
passing signaling pathway triggered by AAT that involves acti-
vation of CD36, iPLA2β-dependent release of a low molecular 
weight factor. This factor activates metabotropic nAChR receptor 
functions that inhibit the P2X7R as well as activation and release 
of IL-1β.
A limitation of our study is that we only describe the general 
lines of a signaling cascade that is probably more complex. For 
instance, the exact mechanism of iPLA2β activation is unknown 
as well as the substrates of this phospholipase. We can only 
speculate on the nature of the released low molecular weight 
factor and even do not know if it is a single active chemical 
substance or a complex mixture. Similarly, metabotropic signal-
ing mechanisms of nAChR are an emerging field of research 
and have to be analyzed in detail (48, 49). In addition, we only 
provide in  vitro and ex vivo evidence for the control of IL-1β 
release. More preclinical and clinical research is warranted to 
estimate the biological and medical relevance of this mechanism.
The strength of our study is that we provide evidence for a very 
efficient pathway by which physiological concentrations of AAT 
inhibit the ATP-induced release of IL-1β by human monocytic 
cells. Our findings might mechanistically explain recent data on a 
large cohort of healthy individuals, in whom a negative correlation 
of AAT and IL-1β blood levels was observed (50). Extracellular 
ATP is a danger molecule and trigger for NLRP3 inflammasome 
activation that is mainly released from the cytoplasm of damaged 
cells. ATP-induced IL-1β release only plays a subordinate role in 
during infection, where other inflammasomes and other mecha-
nisms of caspase activation dominate (2). Hence, we provide first 
evidence for an AAT-mechanism that has the potential to protect 
against sterile, trauma-associated SIRS, without preventing host 
defense against infections. In addition, we discovered a triple-
membrane-spanning signal transduction mechanism involving 
CD36, iPLA2β, and nAChR that might regulate other functions 
in immunity and beyond.
Our results suggest that physiological concentrations of AAT 
might act as an endogenous safeguard against overshooting 
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inflammation mediated by extracellular ATP. The potential 
clinical use of AAT for the prevention of trauma-associated SIRS 
deserves further investigation.
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